Organisation chart: Stakeholders and Communication
Submitted by Anonymous (not verified) on 1 August 2023 - 14:28
Organisation chart: Stakeholders and Communication
Questions and answers (Q&As) on the external guidance of Policy 0070 on clinical data publication (CDP)
Submitted by Anonymous (not verified) on 1 August 2023 - 11:50
Questions and answers (Q&As) on the external guidance of Policy 0070 on clinical data publication (CDP)
Opinion/decision on a Paediatric investigation plan (PIP): Rimegepant, decision type: , therapeutic area: , PIP number: P/0285/2020
Submitted by Anonymous (not verified) on 1 August 2023 - 10:12
Opinion/decision on a Paediatric investigation plan (PIP): Rimegepant, decision type: , therapeutic area: , PIP number: P/0285/2020
Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Desensitization, Immunologic;Kidney Transplantation, Date of authorisation: 25/08/2020, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 1 August 2023 - 9:39
Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Desensitization, Immunologic;Kidney Transplantation, Date of authorisation: 25/08/2020, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Soft Tissue Infections;Skin Diseases, Bacterial, Date of authorisation: 19/02/2015, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 1 August 2023 - 9:03
Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Soft Tissue Infections;Skin Diseases, Bacterial, Date of authorisation: 19/02/2015, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Ofev, nintedanib, Idiopathic Pulmonary Fibrosis, Date of authorisation: 14/01/2015, Revision: 24, Status: Authorised
Submitted by Anonymous (not verified) on 1 August 2023 - 8:08
Human medicines European public assessment report (EPAR): Ofev, nintedanib, Idiopathic Pulmonary Fibrosis, Date of authorisation: 14/01/2015, Revision: 24, Status: Authorised
Human medicines European public assessment report (EPAR): Bydureon, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 17/06/2011, Revision: 25, Status: Authorised
Submitted by Anonymous (not verified) on 1 August 2023 - 7:30
Human medicines European public assessment report (EPAR): Bydureon, exenatide, Diabetes Mellitus, Type 2, Date of authorisation: 17/06/2011, Revision: 25, Status: Authorised
FDIME Announces Research Grants in 2023
Submitted by Aneta on 12 June 2023 - 14:52
The Foundation for the Development of Internal Medicine in Europe (FDIME) is offering Research Grants to Young Internists (up to age 38 yrs) to study in:
Research projects including all fields of General Internal Medicine, particularly polymorbidity and other common Interna Medicine conditions.
For details check the FDIME Research Grants webpage at www.fdime.org
OR
Download the Internal Medicine Grant Announcement and Application Form below.
For further information:
EFIM Annual Report 2022
Submitted by Aneta on 11 May 2023 - 12:45
We are proud to present you with the most significant achievements of 2022 published in EFIM Annual Report!
EFIM Annual report showcases important milestones in 2022, achievements of the WGs, collaboration with our partners and stakeholders allowing all our members to explore each activitiy of EFIM through additional documents, and infographics!
Enjoy reading EFIM Annual Report 2022!
8th EFIM Day - 13 October Brussels
Submitted by Aneta on 8 May 2023 - 15:54
It is our great pleasure and honour to announce that the following EFIM Day will take place once again face to face in Brussels close to our Headquarter on Friday 13 October .
We would like to extent an invitation to the Presidents, the Board Members and the Young Internists of EFIM National Societies to join EFIM in discussing different Internal Medicine’s topics on a European level including EFIM new projects and current activities.